CA2856043A1 - Formulation nasale - Google Patents

Formulation nasale Download PDF

Info

Publication number: CA2856043A1
Authority: CA; Canada
Prior art keywords: formulation; azelastine; aerosol canister; hydrochloric acid; pharmaceutical solution
Prior art date: 2011-12-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA2856043A

Other languages

English (en)

Other versions

CA2856043C (fr

Inventor

Xian-Ming Zeng

Jade Ching-Ying LY

Mukul C DALVI

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teva Branded Pharmaceutical Products R&D Inc

Original Assignee

Teva Branded Pharmaceutical Products R&D Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-07

Filing date

2012-12-04

Publication date

2013-06-13

2012-12-04 Application filed by Teva Branded Pharmaceutical Products R&D Inc filed Critical Teva Branded Pharmaceutical Products R&D Inc

2013-06-13 Publication of CA2856043A1 publication Critical patent/CA2856043A1/fr

2017-01-17 Application granted granted Critical

2017-01-17 Publication of CA2856043C publication Critical patent/CA2856043C/fr

Status Expired - Fee Related legal-status Critical Current

2032-12-04 Anticipated expiration legal-status Critical

Links

239000000203 mixture Substances 0.000 title claims abstract description 83
238000009472 formulation Methods 0.000 title claims abstract description 77
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims abstract description 57
229960004574 azelastine Drugs 0.000 claims abstract description 54
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims abstract description 42
229950000210 beclometasone dipropionate Drugs 0.000 claims abstract description 41
239000003380 propellant Substances 0.000 claims abstract description 20
239000002253 acid Substances 0.000 claims abstract description 19
239000006184 cosolvent Substances 0.000 claims abstract description 9
239000000443 aerosol Substances 0.000 claims description 46
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 44
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
239000003186 pharmaceutical solution Substances 0.000 claims description 28
239000012458 free base Substances 0.000 claims description 22
239000000243 solution Substances 0.000 claims description 18
239000007922 nasal spray Substances 0.000 claims description 12
229940097496 nasal spray Drugs 0.000 claims description 11
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 10
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 8
210000003928 nasal cavity Anatomy 0.000 claims description 7
238000011282 treatment Methods 0.000 claims description 6
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 5
201000010105 allergic rhinitis Diseases 0.000 claims description 4
206010039094 Rhinitis perennial Diseases 0.000 claims description 3
208000036284 Rhinitis seasonal Diseases 0.000 claims description 3
229960004756 ethanol Drugs 0.000 claims description 3
229960000443 hydrochloric acid Drugs 0.000 claims description 3
208000017022 seasonal allergic rhinitis Diseases 0.000 claims description 3
238000012546 transfer Methods 0.000 claims description 3
238000011321 prophylaxis Methods 0.000 claims description 2
239000004480 active ingredient Substances 0.000 description 18
239000003814 drug Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
150000005828 hydrofluoroalkanes Chemical class 0.000 description 8
210000001331 nose Anatomy 0.000 description 8
239000004094 surface-active agent Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 8
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
206010070488 Upper-airway cough syndrome Diseases 0.000 description 2
-1 azelastine Chemical compound 0.000 description 2
YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical group Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
239000013066 combination product Substances 0.000 description 2
229940127555 combination product Drugs 0.000 description 2
239000013065 commercial product Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
239000012535 impurity Substances 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
229910000838 Al alloy Inorganic materials 0.000 description 1
229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
244000250129 Trigonella foenum graecum Species 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229940089206 anhydrous dextrose Drugs 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
229960004335 azelastine hydrochloride Drugs 0.000 description 1
229940098032 beconase Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000001273 butane Substances 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000000938 histamine H1 antagonist Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
229940014206 metered dose nasal spray Drugs 0.000 description 1
238000000034 method Methods 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000002991 molded plastic Substances 0.000 description 1
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
229940002297 nasacort Drugs 0.000 description 1
229940003691 nasonex Drugs 0.000 description 1
229920006120 non-fluorinated polymer Polymers 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
208000022719 perennial allergic rhinitis Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Dispersion Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA2856043A 2011-12-07 2012-12-04 Formulation nasale Expired - Fee Related CA2856043C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201161567893P	2011-12-07	2011-12-07
US61/567,893		2011-12-07
GB1121812.0		2011-12-19
GBGB1121812.0A GB201121812D0 (en)	2011-12-07	2011-12-19	NAsal formulation
PCT/EP2012/074374 WO2013083569A1 (fr)	2011-12-07	2012-12-04	Formulation nasale

Publications (2)

Publication Number	Publication Date
CA2856043A1 true CA2856043A1 (fr)	2013-06-13
CA2856043C CA2856043C (fr)	2017-01-17

Family

ID=48693842

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2856043A Expired - Fee Related CA2856043C (fr)	2011-12-07	2012-12-04	Formulation nasale

Country Status (14)

Country	Link
US (1)	US20130167838A1 (fr)
EP (1)	EP2788001B1 (fr)
AR (1)	AR089101A1 (fr)
CA (1)	CA2856043C (fr)
DK (1)	DK2788001T3 (fr)
ES (1)	ES2560029T3 (fr)
GB (1)	GB201121812D0 (fr)
HU (1)	HUE026612T2 (fr)
IL (1)	IL232944A0 (fr)
MX (1)	MX2014006769A (fr)
PL (1)	PL2788001T3 (fr)
TW (1)	TWI468193B (fr)
UY (1)	UY34496A (fr)
WO (1)	WO2013083569A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014160440A1 (fr)	2013-03-13	2014-10-02	Flatley Discovery Lab	Composés de pyridazinone et procédés pour le traitement de fibrose kystique
GB201408229D0 (en)	2014-05-09	2014-06-25	Norton Waterford Ltd	Aerosol device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9805938D0 (en)	1998-03-19	1998-05-13	Glaxo Group Ltd	Valve for aerosol container
GB2389530B (en) *	2002-06-14	2007-01-10	Cipla Ltd	Pharmaceutical compositions
TW200522932A (en)	2003-09-15	2005-07-16	Combinatorx Inc	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2006102494A2 (fr) *	2005-03-23	2006-09-28	Elan Pharma International Limited	Formulations d'un corticosteroide nanoparticulaire et d'un antihistamine
JP5118702B2 (ja) *	2006-08-22	2013-01-16	グラクソグループリミテッド	吸入器用アクチュエータ
GB0719257D0 (en) *	2007-10-04	2007-11-14	3M Innovative Properties Co	Metered dose dispenser
GB0721739D0 (en) *	2007-11-06	2007-12-19	3M Innovative Properties Co	medicinal inhalation devices and components thereof
EP2926855B1 (fr) *	2010-10-12	2018-12-05	Ivax Pharmaceuticals Ireland	Dispositif de pulvérisation nasale

2011
- 2011-12-19 GB GBGB1121812.0A patent/GB201121812D0/en not_active Ceased
2012
- 2012-12-04 CA CA2856043A patent/CA2856043C/fr not_active Expired - Fee Related
- 2012-12-04 WO PCT/EP2012/074374 patent/WO2013083569A1/fr not_active Ceased
- 2012-12-04 MX MX2014006769A patent/MX2014006769A/es unknown
- 2012-12-04 PL PL12797884T patent/PL2788001T3/pl unknown
- 2012-12-04 HU HUE12797884A patent/HUE026612T2/hu unknown
- 2012-12-04 EP EP12797884.9A patent/EP2788001B1/fr not_active Not-in-force
- 2012-12-04 ES ES12797884.9T patent/ES2560029T3/es active Active
- 2012-12-04 DK DK12797884.9T patent/DK2788001T3/en active
- 2012-12-06 UY UY0001034496A patent/UY34496A/es not_active Application Discontinuation
- 2012-12-06 AR ARP120104578A patent/AR089101A1/es not_active Application Discontinuation
- 2012-12-07 US US13/708,314 patent/US20130167838A1/en not_active Abandoned
- 2012-12-07 TW TW101146277A patent/TWI468193B/zh not_active IP Right Cessation
2014
- 2014-06-02 IL IL232944A patent/IL232944A0/en unknown

Also Published As

Publication number	Publication date
DK2788001T3 (en)	2016-02-01
US20130167838A1 (en)	2013-07-04
TWI468193B (zh)	2015-01-11
CA2856043C (fr)	2017-01-17
HUE026612T2 (hu)	2016-06-28
HK1200342A1 (zh)	2015-08-07
EP2788001B1 (fr)	2015-12-02
MX2014006769A (es)	2015-01-16
WO2013083569A1 (fr)	2013-06-13
UY34496A (es)	2014-05-30
AR089101A1 (es)	2014-07-30
TW201330879A (zh)	2013-08-01
ES2560029T3 (es)	2016-02-17
IL232944A0 (en)	2014-07-31
EP2788001A1 (fr)	2014-10-15
GB201121812D0 (en)	2012-02-01
PL2788001T3 (pl)	2016-04-29

Publication	Publication Date	Title
US10188811B2 (en)	2019-01-29	Nasal spray device
US10960154B2 (en)	2021-03-30	Aerosol device
CA2856043C (fr)	2017-01-17	Formulation nasale
HK1200342B (en)	2016-12-30	Nasal formulation
US20110182830A1 (en)	2011-07-28	Inhalation drug products, systems and uses
AU2015201102B2 (en)	2017-01-05	Nasal spray device
HK1214990B (en)	2019-11-22	Nasal spray device

Legal Events

Date	Code	Title	Description
2014-07-11	EEER	Examination request	Effective date: 20140515
2019-01-15	MKLA	Lapsed	Effective date: 20181204